Survodutide: The Complete Guide

Survodutide (development code BI 456906) is a peptide GLP-1 receptor + glucagon receptor dual agonist. Co-developed by Boehringer Ingelheim and Zealand Pharma, originally optimized in the Zealand discovery program.

Receptor profile:

Survodutide is a mechanism-class twin with mazdutide — both are GLP-1 + glucagon dual agonists, distinct from tirzepatide (GLP-1 + GIP) and retatrutide (triple GLP-1 + GIP + glucagon).

Regulatory status (as of May 2026):

• FDA (US): not approved. FDA Breakthrough Therapy Designation granted September 2024 for non-cirrhotic MASH with significant fibrosis. Multiple Phase 3 trials enrolling.
• EMA (EU): not approved.
• Anywhere else: not approved. Mazdutide is the only GLP-1/glucagon dual agonist approved anywhere in the world (China NMPA, 2025); survodutide is approved nowhere.
• WADA 2026: not on the Prohibited List by name. Glucagon-receptor activation increases energy expenditure — potentially relevant to S4 (metabolic modulators); athletes should consult their governing body.

Same dual mechanism as mazdutide:

GLP-1R activation:

• Glucose-dependent insulin secretion.
• Glucagon suppression in hyperglycemia.
• Delayed gastric emptying.
• Central appetite suppression.

Glucagon receptor (GCGR) activation:

• Increased hepatic energy expenditure.
• Increased fatty-acid oxidation in liver.
• Reduced hepatic lipid accumulation — the source of the strong MASH signal.
• Dose-dependent FGF-21 elevation (a hepatic metabolic-flexibility hormone) per Zimmermann 2022 (PMID 36356832).

Preclinical pharmacology:

Zimmermann et al. Mol Metab 2022 (PMID 36356832): BI 456906 30 nmol/kg outperformed semaglutide 20 nmol/kg on body weight in DIO mice over 4 weeks. Mechanism-consistent FGF-21 elevation and cholesterol/triglyceride reduction.

Phase 2 MASH (the headline study):

Sanyal AJ et al. NEJM 2024. PMID 38847460. Biopsy-confirmed non-cirrhotic MASH (F1–F3 fibrosis), 48 weeks. 4.8 mg dose: histologic MASH improvement without fibrosis worsening in 62% of participants vs 14% on placebo. Among the largest signals reported for any incretin in MASH.

Phase 2 obesity dose-finding:

le Roux CW et al. Lancet Diabetes Endocrinol 2024. PMID 38330987.

Phase 2 T2DM:

Blüher M et al. Diabetologia 2024. PMID 38095657. Includes a semaglutide open-label reference arm.

Phase 1b cirrhosis PK:

Lawitz EJ et al. J Hepatol 2024. PMID 38857788. Single 0.3 mg dose in Child-Pugh A/B/C cirrhosis vs healthy controls; escalating weekly doses up to 6.0 mg over 24 weeks. No PK-driven dose adjustment needed in hepatic impairment — clinically important for the MASH program.

Phase 3 SYNCHRONIZE program (in progress):

• SYNCHRONIZE-1 — obesity, 76 weeks. Topline: −16.6% body weight on the higher dose (PMID 41187967 baseline; topline disclosed in Boehringer press materials).
• SYNCHRONIZE-2 — obesity in T2DM (PMID 41216778 baseline).
• SYNCHRONIZE-CVOT — cardiovascular outcomes (PMID 39453356 design paper).

Note: some sources have stated "approaching 20% weight loss" — the Phase 3 SYNCHRONIZE-1 topline is −16.6%, not 20%. The 20% figure traces to small Phase 1 high-dose data, not pivotal trials.

Phase 2 dose-response is quadratic:

The 4.8 mg dose outperformed 6.0 mg in the MASH Phase 2 — suggesting a GI-tolerability ceiling. Phase 3 CVOT hedges with both 3.6 mg and 6.0 mg arms.

Survodutide and mazdutide share receptor pharmacology (GLP-1 + glucagon). Differences:

Feature	Survodutide (BI 456906)	Mazdutide (IBI362 / Xinermei)
Sponsor	Boehringer Ingelheim × Zealand Pharma	Eli Lilly → Innovent (China rights)
Approval	None as of May 2026	NMPA-approved June 2025 (obesity), Sept 2025 (T2DM) — China only
Phase 3 lead indication	Obesity + MASH + T2DM + CVOT	Obesity + T2DM (approved); MASH (in progress)
FDA Breakthrough Designation	Yes — non-cirrhotic MASH (Sept 2024)	No
Phase 3 weight loss (highest reported)	−16.6% (SYNCHRONIZE-1 topline)	−18.55% (GLORY-2 9 mg, 60 weeks); −21.0% (Phase 1 16 mg, 20 weeks)
MASH evidence	62% MASH improvement at 4.8 mg, NEJM Phase 2	−71.9% liver fat reduction (GLORY-2 subgroup)
Where it’s available	Investigational only (clinical trials)	China retail; gray-market in US

Survodutide is investigational. The dosing reflects published clinical-trial protocols, not an approved label.

Parameter	Range (per published trials)
Starting dose	0.3 mg weekly SC, escalating
Phase 2 obesity	0.6 mg, 2.4 mg, 3.6 mg, 4.8 mg weekly (le Roux 2024)
Phase 2 MASH	2.4, 4.8, 6.0 mg weekly; 4.8 mg outperformed 6.0 mg on MASH endpoint
Phase 3 SYNCHRONIZE	Up to 6.0 mg weekly
Route	Subcutaneous, once weekly

The quadratic dose-response in MASH — 4.8 mg better than 6.0 mg — reflects a GI tolerability ceiling. Phase 3 CVOT hedges with both 3.6 mg and 6.0 mg arms.

Survodutide’s safety profile in published trials is broadly similar to other incretin-class drugs.

Common (incretin class):

• GI: nausea, vomiting, diarrhea, constipation. Most pronounced during dose escalation.
• Decreased appetite (on-target).
• Injection-site reactions.
• Hypoglycemia uncommon as monotherapy; rises with concurrent insulin or sulfonylureas.

Class concerns:

• Pancreatitis — class concern.
• Thyroid C-cell tumors — class boxed warning for GLP-1 RAs based on rodent data.
• Gallbladder disease — class concern with rapid weight loss.

Glucagon-arm-specific:

• Possible cardiovascular effects from glucagon receptor activation — characterized in published trial reports.
• Counter-regulatory glucose effects mostly compensated by the GLP-1R arm.

• Personal or family history of medullary thyroid carcinoma (MTC) — class boxed warning.
• Multiple endocrine neoplasia type 2 (MEN-2) — class boxed warning.
• History of pancreatitis — specialist sign-off.
• Pregnancy / breastfeeding — not studied.
• Severe gastroparesis — class concern.
• Type 1 diabetes — not a substitute for insulin.
• Concurrent insulin or sulfonylureas — hypoglycemia risk; physician supervision required.
• Active gallbladder disease — relative caution.

• Mazdutide — GLP-1/glucagon dual agonist, mechanism-class twin. Approved in China (Xinermei).
• Semaglutide — pure GLP-1R; smaller liver-fat reduction.
• Tirzepatide — GLP-1 + GIP (not glucagon). Different receptor combination.
• Retatrutide — triple GLP-1 + GIP + glucagon. Different mechanism.
• Cotadutide — AstraZeneca GLP-1/glucagon dual agonist; same receptor profile as survodutide; development stalled.
• Resmetirom — thyroid hormone receptor β agonist for MASH, FDA-approved 2024. Different mechanism (not an incretin); the only FDA-approved MASH drug.